Ticker Details
Innoviva, Inc. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline.
IPO Date:	November 25, 2008
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$1.75B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 1.45%
Avg Daily Range (30 D):	$0.23 | 1.12%
Avg Daily Range (90 D):	$0.24 | 1.22%

Institutional Daily Volume
Avg Daily Volume:	.64M
Avg Daily Volume (30 D):	.58M
Avg Daily Volume (90 D):	.6M

Trade Size
Avg Trade Size (Sh.):	93
Avg Trade Size (Sh.) (30 D):	47
Avg Trade Size (Sh.) (90 D):	49

Institutional Trades
Total Institutional Trades:	4,460
Avg Institutional Trade:	$1.79M
Avg Institutional Trade (30 D):	$2.02M
Avg Institutional Trade (90 D):	$2.68M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.86M
Avg Closing Trade (30 D):	$2.58M
Avg Closing Trade (90 D):	$3.54M
Avg Closing Volume:	123K

News

Feb 10, 2026 @ 10:55 AM Tetracyclines Market is Poised to Garner Valuation... Source: Astute Analytica

Jan 8, 2026 @ 3:06 PM Biotech Is Heating Up—These 2 Red-Hot Stock... Source: Nathan Reiff

Aug 7, 2025 @ 3:17 AM Innoviva (INVA) Q2 Sales Jump 64% Source: Na

Dec 16, 2024 @ 6:15 AM Basilea announces agreement with Innoviva Specialt... Source: N/A

Jun 18, 2024 @ 5:44 PM Analyst Projects Strong Growth for GSK-Innoviva Pa... Source: Vandana Singh

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$1.3	$1.01	$-.74
Diluted EPS	$1.08	$.77	$-.74
Revenue	$107.8M	$100.28M	$88.63M
Gross Profit	$75.54M	$83.15M	$73.32M
Net Income / Loss	$89.91M	$63.69M	$-46.58M
Operating Income / Loss	$34.58M	$48.75M	$41.43M
Cost of Revenue	$32.26M	$17.14M	$15.32M
Net Cash Flow	$78.98M	$78.44M	$14.13M
PE Ratio	21.58

Splits
Jun 17, 2013	1:100